VXRT Stock News: Vaxart Inc Price plunges on missed revenues ahead of key presentation

  • NASDAQ:VXRT plummets by 25.60% on Monday amidst another rocky day for the NASDAQ.
  • Vaxart Inc misses revenue estimates during its earnings call before the markets opened.
  • Vaxart is preparing to give a presentation for its oral COVID-19 vaccine candidate on Tuesday.

NASDAQ:VXRT has had an awful start to 2021 and after briefly hitting highs of $24.90, the stock has fallen nearly 70% despite having a potentially groundbreaking vaccine coming down the pipe. On Monday, Vaxart shareholders woke up to a surprise as the quarterly earnings call did not quite go as planned. Shares plummeted by 25.60% during trading hours, to close the day at $8.02, although much of that has been regained during after hours trading. Vaxart is still trading above both its 50-day and 200-day moving averages, and has still comfortably outpaced the S&P 500 index over the past 52-weeks.

Stay up to speed with hot stocks' news!

The main catalyst for Vaxart’s stock plunge was the disappointing earnings results that the company reported prior to the market open. The losses were far larger than Wall Street estimates as Vaxart had a loss of $0.14 per share compared to a loss of $0.02 in the same quarter last year. Revenue also dropped significantly as Vaxart reported an 83% decline after its Japanese seasonal flu medication fell flat. Vaxart also saw its research and development spending surged by nearly six times the normal amount due to its impending COVID-19 vaccine candidate.

VXRT stock price

Much of the questions surrounding Vaxart’s oral COVID-19 vaccine candidate should be answered tomorrow as the Chief Science Officer for Vaxart will be presenting at the World Vaccine Congress Washington 2021. The presentation is believed to focus on the benefits of an oral vaccine rather than an injection, which is what a majority of the world is delivering. Perhaps investors are buying up Vaxart after hours at the discounted price, in hopes that tomorrow’s presentation reveals a promising new treatment for COVID-19.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Are you new or have been trading for a while and you feel stuck?

Try with us!Become Premium!    

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD pressured toward 1.20 on dollar strength

EUR/USD has extended its gains toward 1.20 as the safe-haven dollar gains ground. Fed Chair Powell described the recovery as "patchy" and worries about the virus are also weighing on investors. 


GBP/USD falls under 1.39 on dollar strength, Brexit concerns

GBP/USD is trading below 1.39, down on the day. While the UK made a post-Brexit deal with India. France rejects Britain's provisional changes to fishing licenses. Virus woes weigh on risk sentiment, UK Final Manufacturing PMI, Brexit chatters in focus.


XAU/USD retreats further from two-week tops, weakens to $1,780 area

Gold witnessed some selling on Tuesday and eroded a part of the overnight gains to two-week tops. Resurgent USD demand, a modest pickup in the US bond yields exerted some pressure on the metal.

Gold News

Ripple sets the stage for 40% advance

XRP price has retraced to a crucial support barrier at $1.42. On-chain metrics like Network Profit and loss and MVRV suggest a reset due to recent crash. A bounce from the demand zone extending from $1.33 to $1.40 could trigger a 40% bull rally.

Read more

With a million new jobs looming, why can’t the dollar rally?

The U.S. dollar kicked off the first trading day of May with broad-based losses. On Friday, U.S. non-farm payrolls are due for release and with the labor department expected to report a million new jobs, some investors are wondering why the U.S. dollar is unable to rally. 

Read more